LONDON - Hemogenyx Pharmaceuticals plc announced today that its shareholders have approved all resolutions during an Extraordinary General Meeting (EGM), including the restructuring of the company's share capital. The EGM, which took place earlier today, saw a significant majority of votes cast in favor of the proposed resolutions.
The company's proxy voting results revealed strong shareholder support, with over 95% of votes in favor of both the subdivision and reclassification of existing ordinary shares and the consolidation of the New Ordinary Shares. Additionally, over 92% of votes supported granting the directors authority to allot and issue shares.
Specifically, the first resolution to reclassify existing ordinary shares received 95.39% votes in favor, while the second resolution regarding the consolidation of New Ordinary Shares garnered 95.41% approval. The third resolution, which grants authority to issue shares, was supported by 92.24% of votes.
A special resolution to adopt new articles of association was also passed with 94.80% of the votes. Furthermore, the statutory rights of pre-emption were dis-applied for the allotment of equity securities for cash with 92.78% approval.
The total votes cast represented 38.74% to 38.79% of the company's issued share capital (ISC) as of December 5, 2024, the date when members were registered to be entitled to attend and vote at the meeting.
Votes withheld, which are not considered legal votes and are not counted in the calculation of votes for or against the resolutions, ranged from 1,494,053 to 12,167,035 across the different resolutions.
The resolutions passed at the EGM are expected to be made available for inspection at the National Storage Mechanism in due course. This announcement is based on a press release statement from Hemogenyx Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.